When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.

The IBD category overall is becoming increasingly crowded, however, with other rivals including Johnson & Johnson’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) and Takeda Pharma’s α4β7 ...

It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

This paradigm shift highlights a key role for the interleukin (IL)-23 cytokine, rather than the previous emphasis on IL-12, as the driving force behind the persistent inflammatory reaction.

PsA Risk Similar With IL-23 and IL-12/23 Inhibitors A study found no significant differences in the risk for PsA among patients with psoriasis treated with interleukin (IL)-23 inhibitors and those ...

The majority of gastroenterologists preferred Skyrizi over Stelara in terms of overall efficacy, aligning with the results of the SEQUENCE trial, which demonstrated Skyrizi's superior efficacy in a ...

Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of ...

transforming growth factor-β (TGFβ), IL-12 and IL-23. In turn, T cells drive inflammation via IL-17 release and by cognate interactions with adjacent macrophages. B cells have a critical role in ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.